跳至主要内容
临床试验/IRCT20150221021159N7
IRCT20150221021159N7招募中3 期

Evaluation of the efficacy of Atorvastatin in the management of critically ill COVID-19 patients: A Randomized-controlled clinical trial

Esfahan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age 18 years or older
  • Diagnosis of COVID-19 by RT PCR test and CT scan of the lung and the opinion of the specialist physician
  • Hospitalization in the intensive care unit
  • Full consent and acceptance of the patient or their legal guardian to recruit in the study
  • Possibility to follow the patient for at least 7 days

排除标准

  • Contraindications to the use of atorvastatin include allergic reactions to the drug, active liver disease or persistent and unexplained increase in liver enzymes, pregnancy and lactation, severe hepatic or renal insufficiency (clcr <30 ml / min)
  • Malignancy or underlying immunodeficiency or concomitant use of immunosuppressive drugs
  • Intubated patient under care with mechanical ventilation

研究者

相似试验

Effect of Atorvastatin in the management of COVID-19 | 临床试验